Pari Pharma Gmbh

Patara Pharma, LLC

Polyphor Ag

Respivant Sciences Gmbh

Gilead Sciences, Inc.

Meiji Seika Pharma Co., Ltd.

Pari Gmbh

Respivant Services Gmbh

Kamada Ltd.

Spexis Ag

Manfred Keller

Pravin L Soni

William Gerhart

Ahmet Tutuncu

Johann Zimmermann

Christian Ludin

Martin Luber

Uwe Schuschnig

Eric Chevalier

Ralf Mehrwald

Philip Barth

Piet Bruijnzeel

Masashi Tanaka

Michael Hahn

Alan Bruce Montgomery

Martin Knoch

Roman Egle

Frank-Christophe Lintz

Andreas Böhm

Aslihan Akkar

Ingo Friedrich

Shabtai Bauer

Kuniko Shoji

Nao Sano

Yukihiro Yagi

Toshie Sugano

Jürgen Jauernig

Jurgen Jauernig

Juergen Jauernig

Evy Corbanie

Andreas Bohm

The present invention relates to pharmaceutical aerosols comprising a β-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-Pro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity. Thus, the invention further relates to a pharmaceutical composition or a pharmaceutical aerosol comprising the active compound cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-Pro-Pro-), or any pharmaceutically acceptable salt thereof, for use in a method for the prevention, management or treatment of diseases or conditions of the lungs being mediated by or resulting from human neutrophil elastase activity in a subject.

Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof

The present invention relates to pharmaceutical aerosols comprising a &#x3b2;-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-Pro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity. Thus, the invention further relates to a pharmaceutical composition or a pharmaceutical aerosol comprising the active compound cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-Pro-Pro-), or any pharmaceutically acceptable salt thereof, for use in a method for the prevention, management or treatment of diseases or conditions of the lungs being mediated by or resulting from human neutrophil elastase activity in a subject.

Compositions and methods for the treatment of respiratory syncytial virus infections are provided.

Methods of treating respiratory syncytial virus infections

Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

Mast cell stabilizers treatment for systemic disorders

A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nose, the osteomeatal complex or a paranasal sinus. The pressure of the aerosol is not constant, but pulsates at a frequency from about 10 to 90 Hz. The aerosol is further characterised in that it exhibits a low effective flow rate of less than about 5 liters per minute. The aerosol is, inter alia, suitable for the prevention, management, or treatment of a disease, symptom, or condition affecting the nose or the paranasal sinuses, such as acute and chronic sinusitis.

Aerosols for sinunasal drug delivery

The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome solubilized. The inventive composition is suitable for oral, parenteral, nasal, mucosal, topical, and particularly pulmonary application in the form of an aerosol.

Pharmaceutical compositions comprising cyclosporin

Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided. Some embodiments relate to dosage forms. Dosage forms can include an aqueous pharmaceutical composition containing (i) from about 2% to about 6% by weight of cromolyn sodium, and (ii) an osmolarity adjusting agent consisting of (A) between about 0.1% to about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (B) optionally salts of EDTA; and an inhalation device that forms an aerosol of said pharmaceutical composition, said aerosol exhibiting a respirable fraction of said pharmaceutical composition (&#x3c;5 &#x3bc;m) as measured by USP &#x3c;1601&#x3e; of at least about 60%, are provided.

The invention provides aqueous liquid pharmaceutical compositions comprising arbekacin and chloride ions. The compositions are well tolerable for use in a method for treatment or prevention of a disease of the upper or lower respiratory tract, wherein the composition is aerosolized and inhaled by the patient. Furthermore, the invention provides arbekacin hydrochloride.

Aqueous compositions comprising arbekacin

Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders

Liquid aqueous pharmaceutical solutions, containing a mast cell stabilizing active agent for application to the upper and lower respiratory tract or in the eye are provided. The solutions comprise both a non-ionic and an ionic tonicity-adjusting excipient. They are particularly useful for the aerosol treatment of respiratory diseases such as asthma. Furthermore, methods for nebulization of these solutions and methods of packaging the solutions are provided.

Concentrated mast cell stabilizing pharmaceutical formulations

Growing community of inventors

Munich, Germany

Manfred Keller